sofosbuvir and daclatasvir for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
Roozbeh IRCT20200403046926N1		RCT	sofosbuvir and daclatasvir	standard of care	COVID 19 outpatients
bias due to missing outcome data	some concern
bias in measurement of the primary outcome	some concern
bias in selection of the reported result	some concern

" >some concern
30/30

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis